The time is now: Achieving FH paediatric screening across Europe – The Prague Declaration

  1. Nicole Bedlington 1
  2. Marianne Abifadel 353637
  3. Birgit Beger 21
  4. Mafalda Bourbon 2223
  5. Héctor Bueno 1516171819
  6. Richard Ceska 42
  7. Kristýna Cillíková 2
  8. Zdenka Cimická 2
  9. Magdalena Daccord 1
  10. Carine de Beaufort 20
  11. Kanika I. Dharmayat 7
  12. Brian A. Ference 32
  13. Tomáš Freiberger 4344
  14. Marius Geanta 1
  15. Samuel S. Gidding 1
  16. Urh Grošelj 2728
  17. Martin Halle 34
  18. Neil Johnson 13
  19. Tanja Novakovic 5
  20. Ondrej Májek 3839
  21. Athanasios Pallidis 6
  22. Noel Peretti 1011
  23. Fausto J. Pinto 2526
  24. Kausik Kosh Ray 78
  25. Bleddyn Rees 3334
  26. John Reeve 1
  27. Željko Reiner 41
  28. Raul D. Santos 293031
  29. Heribert Schunkert 12
  30. Jaka Šikonja 27
  31. Milka Sokolovic 24
  32. Lale Tokgözoglu 89
  33. Michal Vrablík 4546
  34. Albert Wiegman 40
  35. Iñaki Gutiérrez-Ibarluzea 14
  36. Mostrar todos los/as autores/as +
  1. 1 FH Europe, Star House, Rochester, UK
  2. 2 Diagnoza FH, Libáň, Czech Rep
  3. 3 Department of Prevention & Sports Medicine, University Hospital Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
  4. 4 Deutsches Zentrum für Herz-Kreislauf-Forschung, Munich Heart Alliance, Munich, Germany
  5. 5 ZEM Solutions Ltd, Belgrade, Serbia
  6. 6 LDL Greece, Athens, Greece
  7. 7 Imperial Centre for Cardiovascular Disease Prevention, Department of Primary Care and Public Health, Imperial College London, London, UK
  8. 8 European Atherosclerosis Society, Göteborg, Sweden
  9. 9 Department of Cardiology, Hacettepe University, Ankara, Turkey
  10. 10 Department of Pediatric Gastroenterology-Hepatology & Nutrition, Hospices Civil de Lyon HCL, Hôpital Femme Mere Enfant HFME, Bron, France
  11. 11 Univ-Lyon, CarMeN laboratory, INSERM U1060, INRAE U1397, Université Claude Bernard Lyon-1, Oullins, Lyon, France
  12. 12 Deutsches Herzzentrum München, Munich, Germany
  13. 13 Global Heart Hub, Galway, Ireland
  14. 14 Basque Foundation for Health Innovation and Research, Barakaldo, Spain
  15. 15 Centro Nacional de Investigaciones Cardiovasculares, Madrid, Spain
  16. 16 Cardiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain
  17. 17 Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
  18. 18 Centro de Investigación Biomédica en Red Enfermedades Cardiovaculares, Madrid, Spain
  19. 19 Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain
  20. 20 Diabetes & Endocrine Care Clinique Pediatrique/CHL, Luxembourg, Grand Duchy Luxembourg
  21. 21 European Heart Network, European Alliance for Cardiovascular Health, Brussels, Belgium
  22. 22 Unidade de I&D, Grupo de Investigação Cardiovascular, Departamento de Promoção da Saúde e Prevenção de Doenças Não Transmissíveis, Instituto Nacional de Saúde Doutor Ricardo Jorge, Lisboa, Portugal
  23. 23 BioISI – Biosystems & Integrative Sciences Institute, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal
  24. 24 Europan Public Health Alliance, Brussels, Belgium
  25. 25 World Heart Federation, Geneva, Switzerland
  26. 26 Cardiovascular Department, CCUL, CAML, Lisbon School of Medicine, University of Lisbon, Lisbon, Portugal
  27. 27 Department of Endocrinology, Diabetes & Metabolic Diseases, University Children’s Hospital, University Medical Centre Ljubljana, Ljubljana, Slovenia
  28. 28 Faculty of Medicine, University of Ljubljana, Ljubljana, Slovenia
  29. 29 Lipid Clinic Heart Institute, University of Sao Paulo Medical School Hospital, Sao Paulo, Brazil
  30. 30 Hospital Israelita Albert Einstein, Sao Paulo, Brazil
  31. 31 International Atherosclerosis Society, Milan, Italy
  32. 32 University Of Cambridge, Clinical School, Cambridge, UK
  33. 33 The Digital Health Society, Dublin, Ireland
  34. 34 The European Connected Health Alliance, Belfast, UK
  35. 35 Laboratory of Biochemistry & Molecular Therapeutics, Faculty of Pharmacy, Pôle Technologie–Santé, Saint Joseph University of Beirut, Beirut, Lebanon
  36. 36 Laboratory for Vascular Translational Science, Paris Cité University, Paris, France
  37. 37 Sorbonne Paris Nord University, INSERM, Paris, France
  38. 38 National Screening Centre, Institute of Health Information & Statistics of the Czech Republic, Prague, Czech Rep
  39. 39 Institute of Biostatistics & Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Rep
  40. 40 University of Amsterdam, Department of Paediatrics, Amsterdam, Netherlands
  41. 41 University Hospital Center Zagreb, Department for Metabolic Diseases, Zagreb, Croatia
  42. 42 3rd Department of Medicine – Department of Endocrinology & Metabolism of the 1st Faculty of Medicine, Charles University & General University Hospital, Prague, Czech Rep
  43. 43 Centre for Cardiovascular Surgery and Transplantation, Brno, Czech Rep
  44. 44 Medical Faculty, Masaryk University, Brno, Czech Rep
  45. 45 3rd Department of Internal Medicine, General Teaching Hospital, Prague, Czech Rep
  46. 46 1st Faculty of Medicine, Charles University, Prague, Czech Rep
Mostrar afiliaciones +
Revista:
GMS Health Innovation and Technologies

Año de publicación: 2022

Volumen: 16

Tipo: Artículo

DOI: 10.3205/HTA000136 GOOGLE SCHOLAR lock_openAcceso abierto editor

Resumen

Familial hypercholesterolaemia (FH) is the most common inherited metabolic disorder characterized by high cholesterol and if left untreated leads to premature cardiovascular disease, such as heart attacks. Treatment that begins early in life, particularly in childhood, is highly efficacious in preventing cardiovascular disease and cost-effective, thus early detection of FH is crucial. However, in Europe, less than 10% of people living with FH are diagnosed and even less receive life-saving treatment. The Prague Declaration is a call to action for national and European Union policymakers and decision-makers and a result of the Czech EU Presidency meeting on FH Paediatric Screening (early detection of inherited high cholesterol) at the Czech Senate in Prague on 6th September 2022. It builds on a considerable body of evidence which was discussed at the Technical Meeting under the auspices of the Slovenian EU Presidency in October 2021. The Prague meeting addressed the outstanding barriers to the systematic implementation of FH paediatric screening across Europe. In this article, we present the key points from the Prague meeting and concrete actions needed to move forward.